Profile data is unavailable for this security.
About the company
RenovoRx, Inc. is a clinical-stage biopharmaceutical company. The Company is developing targeted combination therapies for high unmet medical needs with a goal of improving therapeutic outcomes for cancer patients undergoing treatment. Its Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. Its portfolio of cancer therapies is based on its lead product candidate, RenovoGem (gemcitabine delivered via its delivery system). Its phase III lead product candidate, RenovoGem, is a novel oncology drug-device combination product. RenovoGem is being evaluated for the treatment of locally advanced pancreatic cancer (LAPC) by the Center for Drug Evaluation and Research. Its phase III registrational trial of RenovoGem for the treatment of LAPC is called TIGeR-PaC.
- Revenue in USD (TTM)0.00
- Net income in USD-9.16m
- Incorporated2012
- Employees8.00
- LocationRenovoRx Inc333 W Santa Clara St Ste 900SAN JOSE 95113-1716United StatesUSA
- Phone+1 (408) 800-2649
- Fax+1 (302) 636-5454
- Websitehttps://renovorx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Marker Therapeutics Inc | 5.40m | -9.63m | 26.34m | 8.00 | -- | 3.53 | -- | 4.88 | -1.08 | -1.09 | 0.6057 | 0.837 | 0.355 | -- | 13.04 | 674,481.30 | -63.39 | -53.74 | -79.76 | -62.25 | -- | -- | -178.54 | -1,438.71 | -- | -- | 0.00 | -- | -5.76 | 74.27 | 28.97 | -- | -- | -- |
| Lipocine Inc | 7.92m | -4.06m | 26.74m | 17.00 | -- | 1.40 | -- | 3.38 | -0.7626 | -0.7626 | 1.48 | 3.57 | 0.3486 | -- | 119.56 | 466,054.70 | -17.85 | -39.32 | -19.49 | -45.87 | -- | -- | -51.19 | -442.26 | -- | -- | 0.00 | -- | -670.16 | -- | -51.99 | -- | -- | -- |
| DURECT Corp | 8.59m | -17.07m | 26.77m | 45.00 | -- | 22.00 | -- | 3.12 | -0.5556 | -0.5556 | 0.2813 | 0.0392 | 0.2181 | 0.7417 | 9.05 | 148,172.40 | -43.33 | -37.34 | -156.35 | -53.44 | 78.87 | 91.83 | -198.62 | -139.11 | 0.5963 | -24.30 | 0.8958 | -- | -55.67 | -10.96 | 21.82 | -- | -10.98 | -- |
| Mink Therapeutics Inc | 0.00 | -13.78m | 27.28m | 31.00 | -- | -- | -- | -- | -0.3865 | -0.3865 | 0.00 | -0.4439 | 0.00 | -- | -- | 0.00 | -185.76 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 19.77 | -- | -- | -- |
| IGC Pharma Inc | 1.18m | -12.57m | 27.30m | 67.00 | -- | 3.66 | -- | 23.08 | -0.1879 | -0.1879 | 0.0171 | 0.0963 | 0.088 | 0.2499 | 13.07 | 17,656.72 | -93.54 | -42.46 | -114.44 | -46.07 | 56.21 | 20.95 | -1,062.47 | -730.00 | 0.9779 | -- | 0.0184 | -- | 47.64 | -23.45 | -12.98 | -- | 53.72 | -- |
| Eterna Therapeutics Inc | 598.00k | -44.95m | 27.34m | 8.00 | -- | -- | -- | 45.72 | -8.31 | -8.31 | 0.1105 | -8.39 | 0.0199 | -- | 0.6093 | 74,750.00 | -149.86 | -169.05 | -222.51 | -223.00 | 72.91 | -- | -7,513.88 | -682.61 | -- | -5.43 | -- | -- | -- | -68.89 | 11.84 | -- | -58.86 | -- |
| Hookipa Pharma Inc | 50.00m | -43.37m | 27.73m | 151.00 | -- | 0.3861 | -- | 0.5545 | -4.11 | -4.11 | 4.24 | 5.96 | 0.3653 | -- | 100.10 | 331,119.20 | -31.69 | -41.63 | -42.40 | -50.26 | -- | -- | -86.74 | -366.65 | -- | -- | 0.00 | -- | 41.27 | 21.41 | -25.67 | -- | 14.11 | -- |
| Longeveron Inc | 1.85m | -27.37m | 27.74m | 23.00 | -- | 1.08 | -- | 14.98 | -6.67 | -6.67 | 0.2962 | 1.73 | 0.0892 | -- | 7.78 | 80,521.74 | -86.28 | -63.15 | -102.27 | -75.68 | 73.06 | 33.70 | -967.49 | -441.02 | -- | -- | 0.00 | -- | -41.98 | -19.78 | -17.92 | -- | 26.80 | -- |
| SAB Biotherapeutics Inc | 1.51m | -45.57m | 28.33m | 57.00 | -- | 0.7678 | -- | 18.73 | -5.84 | -5.84 | 0.1753 | 4.00 | 0.0368 | -- | 31.17 | 26,539.12 | -110.96 | -- | -142.16 | -- | -- | -- | -3,012.26 | -- | -- | -- | 0.0856 | -- | -90.63 | -- | -125.14 | -- | -- | -- |
| RenovoRx Inc | 0.00 | -9.16m | 29.03m | 8.00 | -- | 4.11 | -- | -- | -0.572 | -0.572 | 0.00 | 0.2946 | 0.00 | -- | -- | 0.00 | -135.25 | -- | -180.14 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3.47 | -- | -- | -- |
| Chemomab Therapeutics Ltd - ADR | 0.00 | -14.40m | 29.61m | 20.00 | -- | 1.85 | -- | -- | -0.9868 | -0.9868 | 0.00 | 0.8654 | 0.00 | -- | -- | 0.00 | -64.98 | -- | -83.24 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 12.39 | -- | -- | -- |
| Hcw Biologics Inc | 3.50m | -37.33m | 29.79m | 45.00 | -- | -- | -- | 8.52 | -1.00 | -1.00 | 0.0939 | -0.2636 | 0.1125 | -- | 5.13 | 77,688.45 | -120.09 | -- | -279.71 | -- | 32.41 | -- | -1,067.83 | -- | -- | -93.78 | 4.52 | -- | -57.72 | -- | -67.74 | -- | -- | -- |
| Impact Biomedical Inc | 0.00 | 1.16m | 30.12m | 1.00 | 25.98 | 0.9633 | 13.58 | -- | -0.2094 | -0.2094 | 0.00 | 2.72 | 0.00 | -- | -- | 0.00 | 2.39 | -- | 3.04 | -- | -- | -- | -- | -- | -- | -- | 0.189 | -- | -100.00 | -- | 38.51 | -- | -- | -- |
| Surrozen Inc | 10.00m | -44.44m | 30.22m | 42.00 | -- | 5.33 | -- | 3.02 | -17.05 | -17.05 | 3.81 | 1.74 | 0.1961 | -- | 1.41 | 238,095.20 | -87.16 | -- | -99.66 | -- | -- | -- | -444.38 | -- | -- | -1.43 | 0.00 | -- | -100.00 | -- | -19.55 | -- | -- | -- |
| Clene Inc. | 421.00k | -36.02m | 30.40m | 82.00 | -- | -- | -- | 72.22 | -5.58 | -5.58 | 0.0652 | -0.6016 | 0.0092 | 0.7759 | 13.16 | 5,134.15 | -78.31 | -39.43 | -136.18 | -47.32 | 78.62 | -- | -8,556.77 | -5,261.20 | 0.8213 | -10.15 | 1.30 | -- | 38.27 | -- | -65.47 | -- | -- | -- |
| Promis Neurosciences Inc | 0.00 | -563.35k | 31.22m | 6.00 | -- | 4.29 | -- | -- | -0.1931 | -0.1931 | 0.00 | 0.2225 | 0.00 | -- | -- | 0.00 | -2.66 | -144.28 | -3.77 | -262.23 | -- | -- | -- | -2,271,047.00 | -- | -- | 0.00 | -- | -- | -- | 26.85 | -- | -- | -- |
Data as of Nov 22 2024. Currency figures normalised to RenovoRx Inc's reporting currency: US Dollar USD
7.85%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BMO Family Office LLCas of 30 Sep 2024 | 975.00k | 4.07% |
| Adar1 Capital Management LLCas of 30 Sep 2024 | 315.19k | 1.31% |
| Geode Capital Management LLCas of 30 Sep 2024 | 232.94k | 0.97% |
| Nixon Peabody Trust Co. LLCas of 30 Sep 2024 | 97.17k | 0.41% |
| Millennium Management LLCas of 30 Sep 2024 | 82.35k | 0.34% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 56.74k | 0.24% |
| Charles Schwab Investment Management, Inc.as of 30 Sep 2024 | 49.23k | 0.21% |
| Kestra Advisory Services LLCas of 30 Sep 2024 | 35.52k | 0.15% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 26.15k | 0.11% |
| Affinity Capital Advisors LLCas of 30 Sep 2024 | 13.28k | 0.06% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
